{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_20640", "batch_size": 200, "batch_pos": 64, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment states neutral facts about testing timelines without using high-potency verbs, metaphors, or intensifiers.", "method": "llm_batch", "batch_id": "batch_2_6036", "batch_size": 200, "batch_pos": 53, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb from the specified list paired with scale/impact information.", "method": "llm_batch", "batch_id": "batch_3_17588", "batch_size": 200, "batch_pos": 23, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_18960", "batch_size": 200, "batch_pos": 20, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "Reports a timeline for testing without explicit calming language about current safety.", "method": "llm_batch", "batch_id": "batch_5_20620", "batch_size": 200, "batch_pos": 20, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast for reassurance found.", "method": "llm_batch", "batch_id": "batch_6_3816", "batch_size": 200, "batch_pos": 5, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "Does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_16268", "batch_size": 200, "batch_pos": 199, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "regex:CapabilityNoReassurance matched", "method": "regex", "batch_id": "batch_8_1544", "batch_size": 200, "batch_pos": 116, "regex": {"rule": "CapabilityNoReassurance", "span": [5, 14], "captures": []}, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
